Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and would like to thank the National Cancer Institute for funding Privo’s inclusion as part of this conference.
Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more
The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists at... read more
Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more
Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
Peabody, MA-- Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the... read more
Privo Technologies expands to a new 3,000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place,... read more
Privo a $2.5M grant to optimize it lead product and prepare for its IND. read more
Privo Technologies, Inc. attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year... read more
Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more
- © UX Strategy & Digital Branding